Name: Atrial fibrillation / RVR — bulletproof documentation — ER Toolkit
Creator: Kim Trinh, MD

Rapid AF is often not the disease — it's the alarm bell for sepsis, PE, or ischemia underneath. The defensible chart shows you looked for the precipitant before reaching for a rate-control drug, recognized pre-excitation before giving a nodal blocker, and documented the stroke-prevention decision.

01What's at stake

In a large ED cohort, ~37% of AF/RVR patients had an acute underlying illness — and rate- or rhythm-controlling that compensatory tachycardia was tied to a 6–12-fold rise in adverse events. Two other high-stakes errors: giving an AV-nodal blocker in pre-excited (WPW) AF, and discharging a high-risk patient without addressing anticoagulation (as many as a third leave without it).

02Can't-miss points

AF as a symptom — sepsis, PE, ACS, thyrotoxicosis, hypoxia/COPD, GI bleed/anemia, alcohol. Treat the cause, not just the rate.
Unstable AF — hypotension, ischemic chest pain, acute heart failure, altered mentation → cardioversion (after addressing reversible causes).
Pre-excited (WPW) AF — irregular, wide, very fast (often >220); avoid AV-nodal blockers (diltiazem, beta-blockers, digoxin, adenosine) — use procainamide or electricity.
Valvular AF (mechanical valve / moderate-severe mitral stenosis) — warfarin, not DOACs.
Read the whole ECG — ischemia can coexist with AF.

03History & exam

Fever, infection, dyspnea, chest pain, bleeding, weight loss/tremor? → search for a precipitant
Onset time of the AF (for the cardioversion decision)? → <48h vs ≥48h/unknown
Wide/bizarre QRS or rate >220? → pre-excitation
Mechanical valve / mitral stenosis? → valvular AF (warfarin)

Skip the typing

Work the case in the Atrial Fibrillation / RVR Workup — it records the ECG, troponin, the precipitant search, rate control, and CHA2DS2-VASc, and assembles an MDM that documents the can't-miss points and the disposition.

04Management

Find & treat the precipitant first — rate-controlling a septic/PE-driven tachycardia is harmful; if truly unstable after resuscitation, synchronized cardioversion at high energy.
Rate control (stable, primary AF): beta-blocker or diltiazem; don't stack the two (risk of hypotension/heart block); caution/avoid in HFrEF and pre-excitation; for the borderline-BP patient, smaller diltiazem doses ± fluids/push-dose pressor.
Rhythm control selected patients (onset <48h, anticoagulated, or low risk) — pharmacologic or electrical; all cardioverted patients get ≥4 weeks anticoagulation.
The 48-hour rule — beyond 48h or unknown duration, don't cardiovert without ≥3 weeks anticoagulation or a TEE; even <48h carries small thromboembolic risk (don't treat it as a hard "safe" cutoff).

05Stroke prevention

CHA2DS2-VASc drives anticoagulation (start in men ≥2, women ≥3); DOACs preferred (warfarin for valvular AF); start it in the ED — don't defer entirely to cardiology.
HAS-BLED identifies and addresses modifiable bleeding risk; a high score is not a contraindication to anticoagulation.
Arrange urgent/next-day cardiology follow-up for every discharged patient.

06What to document

▼ weak

"AF with RVR, gave diltiazem 20 mg, rate down, discharged."

▲ defensible

"AF with RVR; assessed for precipitant — afebrile, no infection source, no chest pain/dyspnea to suggest sepsis/PE/ACS (troponin negative, CXR clear). ECG: AF, narrow QRS, no pre-excitation, no ischemia. Onset <24h. Rate controlled with diltiazem (titrated); hemodynamically stable. CHA2DS2-VASc and HAS-BLED documented; anticoagulation decision made with shared decision-making; next-day cardiology follow-up arranged."

07Where charts fail

Rate-controlling a compensatory tachycardia and missing the sepsis/PE underneath.
Giving an AV-nodal blocker in pre-excited AF.
Stacking a beta-blocker and a calcium-channel blocker.
Cardioverting beyond 48h (or unknown onset) without anticoagulation/TEE, or not anticoagulating after cardioversion.
Discharging a high-CHA2DS2-VASc patient without addressing anticoagulation, or missing concurrent ischemia on the ECG.

08Sources

Milman B, Burns BD. Atrial fibrillation: an approach to diagnosis and management in the emergency department. Emergency Medicine Practice (EB Medicine). 2021;23(5).
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update on the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-132.
Scheuermeyer FX, Pourvali R, Rowe BH, et al. ED patients with AF/flutter and an acute underlying medical illness may not benefit from rate/rhythm control. Ann Emerg Med. 2015;65(5):511-522.
Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute AF (FinCV). J Am Coll Cardiol. 2013;62(13):1187-1192.

Atrial fibrillation / RVR: documentation that holds up